Who
Joel Lewis
President and CEO
Company insider
Files Form 4 as: President and CEO, Galectin Therapeutics.
In numbers
- Trades disclosed
- 158
- Buys
- 7
- Sells
- 12
- Bought
- $79K
- Sold
- $1.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Dec 2017
- Last trade
- 16 Jan 2026
- Last filed
- 22 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jan 2026filed 22 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,000 at $0.00 | filing |
| 16 Jan 2026filed 22 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 6 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $135K37,698 at $3.58 | filing |
| 6 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $135K37,698 at $3.58 | filing |
| 5 Jan 2026filed 13 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Other | $219K56,332 at $3.88 | filing |
| 5 Jan 2026filed 13 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Other | $219K56,332 at $3.88 | filing |
| 5 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K27,731 at $3.91 | filing |
| 5 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K27,731 at $3.91 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | —84,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $78K18,571 at $4.20 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —84,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —84,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | —84,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Sold | $78K18,571 at $4.20 | filing |
| 17 Dec 2025filed 19 Dec 2025 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,829 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code M | $22K7,829 at $2.86 | filing |
News
No headline names them, or the companies they trade most, lately.